AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Saved in:
| Title: | AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. |
|---|---|
| Authors: | Oar, Andrew1 (AUTHOR) andrew.oar@icon.team, Lee, Mark2 (AUTHOR), Le, Hien3 (AUTHOR), Wilson, Kate4 (AUTHOR), Aiken, Chris4 (AUTHOR), Chantrill, Lorraine5 (AUTHOR), Simes, John4 (AUTHOR), Nguyen, Nam6 (AUTHOR), Barbour, Andrew7 (AUTHOR), Samra, Jaswinder8 (AUTHOR), Sjoquist, Katrin M.4,9 (AUTHOR), Moore, Alisha10 (AUTHOR), Espinoza, David4 (AUTHOR), Gebski, Val4 (AUTHOR), Yip, Sonia4 (AUTHOR), Chu, Julie11 (AUTHOR), Kneebone, Andrew12 (AUTHOR), Goldstein, David13 (AUTHOR) |
| Source: | BMC Cancer. 8/19/2021, Vol. 21 Issue 1, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 14712407 |
|---|---|
| DOI: | 10.1186/s12885-021-08666-y |
